结肠癌肝转移综合治疗临床效果观察  

Clinical effect of comprehensive treatment of liver metastasis from colon cancer

作　　者：秦敬[1] 

机构地区：[1]湖北省肿瘤医院,430079

出　　处：《首都食品与医药》2017年第10期64-65,共2页Capital Food Medicine

摘　　要：目的抗血管生成药物贝伐珠单抗联合化疗可延长结直肠癌肝转移患者的总生存和无进展生存,且安全性良好,本文重点研究贝伐珠单抗联合化疗治疗结直肠癌肝转移的效果。方法回顾性记录50例患者治疗前后的临床分期,并进行治疗效果评价,为临床治疗提供依据,以期提高直肠癌肝转移的生存率。分别对50例患者进行1年和2年短期随访,记录生存率和复发率。结果综合治疗组和化学治疗组的1年和2年生存率分别为95.2%、52.4%和79.3%、34.5%。χ2检验有统计学差异(χ2=6.62、7.10 P<0.05);局部复发率两组为28.6%、62.1%。χ2检验有统计学差异(χ2=5.89,P<0.05)。结论综合治疗结直肠癌肝转移患者,可以明显提高患者的近期生存率,降低局部复发率,毒副反应较小,临床获益较大。在转移性肿瘤的治疗中应当把治疗分为全身治疗和局部治疗,全身治疗放在第一位,在进行全身治疗的基础上再进行局部治疗效果更好,否则转移灶会不断增多。Background Anti-angiogenic drugs bevacizumab combined with chemotherapy can safely prolong the OS and PFS of patients with liver metastases from colorectal cancer. Methods The clinical stagingof 50 patients before and after treatment was retrospectively recorded. The treatment effect was evaluated, followed by a random survey after 1 or 2 years, which recorded the survival and recurrence. Results One-year and two- year survival rate for the comprehensive treatment group and chemotherapy group were 95.2%, 52.4% and 79.3%, 34.5% respectively. There is a statistical difference （X 2=6.62, P〈0.05） after X 2 analysis. The local recurrence rates of two groups were 28.6% and 62.1%, respectively. There is a statistical difference （X2=5.89, P〈O.05） after X = analysis. Conc I us i on For colorectal cancer therapy with liver metastasis, we can get higher short-term survival rate, lower local recurrence rate, less side effect, and greater clinical benefit using comprehensive treatment. In the treatment of metastatic tumors, we first proposed that treatment is divided into systemic treatment and local treatment. We should give the systemic treatment a higher priority than the local treatment in metastatic tumor therapy, otherwise metastases will increase.

关 键 词：结肠癌 辅助化疗 综合治疗 生存率 

分 类 号：R735.35[医药卫生—肿瘤]